Phenominer Database Results (126 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
LEXF3/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 61.5 % fluorescence-activated cell sorting method 0.0 0 70000 1280
LEXF9/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 27 11.1 % fluorescence-activated cell sorting method 0.0 0 70009 1280
LEXF10A/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 30 80.0 % fluorescence-activated cell sorting method 0.0 0 70010 1280
LEXF1C/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 23 111.0 d 3.46 16.6 fluorescence-activated cell sorting method 0.0 0 70019 1280
LEXF7A/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 25 123.7 d 6.34 31.7 fluorescence-activated cell sorting method 0.0 0 70027 1280
LEXF10A/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 30 130.7 d 5.57 30.5 fluorescence-activated cell sorting method 0.0 0 70033 1280
LEXF11/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 25 116.7 d 6.6 33.0 fluorescence-activated cell sorting method 0.0 0 70036 1280
LEXF8D/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 14 139.6 d 3.61 13.5 fluorescence-activated cell sorting method 0.0 0 70039 1280
BB.SHR-(Gnal-D18Mit9)/K blood CD4 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 34.1 % 2.14 8.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84627 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD8 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD8-positive T cell quantity both 90 days 30 0.7 % 0.13 0.7 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84628 324
BB.SHR-(D6Rat184-D6Rat3)/K blood RT6.1 positive cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 10 1.7 % 0.13 0.4 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84635 324
BB.SHR-(Gnal-D18Mit9)/K blood B lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. B cell quantity both 90 days 14 37.4 % 2.75 10.3 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75600 324
BB.SHR-(D6Rat184-D6Rat3)/K blood T lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 10 10.4 % 0.95 3.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75602 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD45RC(high) CD4 T cell count to CD45RC(low) CD4 T cell count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 10 0.05 % 0.01 0.02 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84689 324
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 21 2.0 x 10E6 cells/ml 0.11 0.51 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111104 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 21 2.1 x 10E6 cells/ml 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111105 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 588.0 cells/ul 49.73 211.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111090 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 16 1917.0 cells/ul 105.25 421.0 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111089 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 16 1.57 x 1000 cells/ul 0.06 0.24 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111109 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 0.96 x 1000 cells/ul 0.06 0.25 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111110 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 2.22 x 1000 cells/ul 0.06 0.26 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111113 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 21 4.5 x 1000 cells/ul 0.23 1.05 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111115 3196
BB.SHR-(Gnal-D18Mit9)/K white blood cell count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. leukocyte quantity both 90 days 14 2.83 x 1000 cells/ul 0.23 0.87 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75606 324
LEW/Rj blood CD45RC(low) CD8 T cell count to total CD8 T cell count ratio control condition Xystrakis E, et al., J Immunol 2004 Sep 1;173(5):3140-7. CD8-positive T cell quantity male 0 days 0 20.0 % 3.0 fluorescence-activated cell sorting method 0.0 0 70570 1479
LEXF1A/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 92.3 % fluorescence-activated cell sorting method 0.0 0 69994 1280
LEXF11/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 25 96.0 % fluorescence-activated cell sorting method 0.0 0 70013 1280
LEXF2D/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 19 124.0 d 3.67 16.0 fluorescence-activated cell sorting method 0.0 0 70615 1280
BB.SHR-(Gnal-D18Mit9)/K blood natural killer cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. natural killer cell quantity both 90 days 14 13.8 % 1.34 5.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84633 324
BB.SHR-(D6Rat184-D6Rat3)/K blood RT6.1 positive cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 30 3.0 % 0.6 3.3 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84634 324
BBDR/Rhw blood CD4 cell to R73 cell ratio specific pathogen-free condition Fuller JM, et al., Physiol Genomics. 2009 Apr 7. T cell quantity not specified 25 days-30 days 75 median 75.0 % fluorescence-activated cell sorting method 0.0 0 67843 690
LEXF8B/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 25 4.0 % fluorescence-activated cell sorting method 0.0 0 70618 1280
LEXF5/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 19 15.8 % fluorescence-activated cell sorting method 0.0 0 70002 1280
LEXF10C/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 76.2 % fluorescence-activated cell sorting method 0.0 0 70012 1280
LEXF8D/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 14 42.9 % fluorescence-activated cell sorting method 0.0 0 70016 1280
LEXF8A/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 17 153.5 d 3.76 15.5 fluorescence-activated cell sorting method 0.0 0 70030 1280
LEXF8C/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 233.0 d 2.24 10.0 fluorescence-activated cell sorting method 0.0 0 70031 1280
F344/DuCrlCrlj post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 29 106.6 d 2.9 15.6 fluorescence-activated cell sorting method 0.0 0 70037 1280
BB.SHR-(D6Rat184-D6Rat3)/K blood CD25 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 10 36.6 % 2.18 6.9 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84638 324
BB.SHR-(D6Rat184-D6Rat3)/K blood lymphocyte count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 10 1.87 x 1000 cells/ul 0.19 0.6 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75596 324
BB.SHR-(Gnal-D18Mit9)/K blood T lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 14 11.8 % 0.78 2.9 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75603 324
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 987.0 cells/ul 23.81 101.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111092 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 16 1631.0 cells/ul 149.75 599.0 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111088 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 77 days-91 days 16 2.25 x 10E6 cells/ml 0.18 0.72 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111097 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 16 0.92 x 10E6 cells/ml 0.03 0.1 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111099 3196
BBDR.F344-(D4Rat153-D4Rhw6),BBDP-(D4Rhw6-D4Rhw10)/Rhw blood R73 cell to total mononuclear cell ratio specific pathogen-free condition Fuller JM, et al., Physiol Genomics. 2009 Apr 7. T cell quantity not specified 25 days-30 days 20 median 9.0 % fluorescence-activated cell sorting method 0.0 0 67847 690
LEXF8C/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 10.0 % fluorescence-activated cell sorting method 0.0 0 70008 1280
BB.SHR-(D6Rat184-D6Rat3)/K blood CD45RC(low) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 10 70.9 % 1.93 6.1 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84686 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD4 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 10 43.3 % 1.9 6.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84626 324
BB.SHR-(Gnal-D18Mit9)/K blood CD45RC(high) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 4.8 % 0.43 1.6 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84684 324
LEXF2D/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 19 10.5 % fluorescence-activated cell sorting method 0.0 0 70617 1280
LEXF2A/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 28.6 % fluorescence-activated cell sorting method 0.0 0 69997 1280
LE/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 11.5 % fluorescence-activated cell sorting method 0.0 0 70015 1280
LEXF1A/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 101.8 d 1.88 9.6 fluorescence-activated cell sorting method 0.0 0 70017 1280
LEXF2C/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 128.4 d 5.72 25.6 fluorescence-activated cell sorting method 0.0 0 70022 1280
LEXF4/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 128.7 d 5.3 24.3 fluorescence-activated cell sorting method 0.0 0 70024 1280
LEXF9/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 27 118.0 d 1.96 10.2 fluorescence-activated cell sorting method 0.0 0 70032 1280
LEXF10B/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 143.3 d 9.82 45.0 fluorescence-activated cell sorting method 0.0 0 70034 1280
BB.SHR-(Gnal-D18Mit9)/K blood lymphocyte count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 14 2.0 x 1000 cells/ul 0.17 0.63 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75597 324
BB.SHR-(D6Rat184-D6Rat3)/K blood natural killer cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. natural killer cell quantity both 90 days 30 13.3 % 1.15 6.3 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84631 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD25 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 30 65.6 % 3.36 18.4 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84637 324
BB.SHR-(D6Rat184-D6Rat3)/K blood lymphocyte count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 30 2.02 x 1000 cells/ul 0.15 0.82 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75595 324
BB.SHR-(D6Rat184-D6Rat3)/K blood T lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 30 11.0 % 0.82 4.5 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75601 324
BB.SHR-(Gnal-D18Mit9)/K blood CD45RC(high) CD4 T cell count to CD45RC(low) CD4 T cell count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 0.08 % 0.01 0.03 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84690 324
BDIX/OrlCrl blood CD25 cell count 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 63 days-77 days 16 661.0 cells/ul 56.75 227.0 fluorescence-activated cell sorting method 0.0 0 days baseline baseline saline control group 111086 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 77 days-91 days 16 2294.0 cells/ul 205.0 820.0 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111087 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 641.0 cells/ul 161.46 685.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111091 3196
BDIX/OrlCrl blood CD8 cell count 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 63 days-77 days 16 1.83 x 10E6 cells/ml 0.23 0.93 fluorescence-activated cell sorting method 0.0 0 days baseline baseline saline control group 111096 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 16 1.17 x 10E6 cells/ml 0.07 0.3 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111098 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 77 days-91 days 16 2.76 x 1000 cells/ul 0.24 0.96 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111107 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 0.3 x 1000 cells/ul 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111111 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 1.88 x 1000 cells/ul 0.07 0.29 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111112 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 21 3.39 x 1000 cells/ul 0.16 0.72 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111114 3196
BBDR/Rhw blood R73 cell to total mononuclear cell ratio specific pathogen-free condition Fuller JM, et al., Physiol Genomics. 2009 Apr 7. T cell quantity not specified 25 days-30 days 75 median 60.0 % fluorescence-activated cell sorting method 0.0 0 67842 690
LEXF1C/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 23 95.6 % fluorescence-activated cell sorting method 0.0 0 69996 1280
LEXF2C/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 85.0 % fluorescence-activated cell sorting method 0.0 0 69999 1280
LEXF10B/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 66.7 % fluorescence-activated cell sorting method 0.0 0 70011 1280
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 21 3664.0 cells/ul 56.74 260.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111095 3196
BB.SHR-(Gnal-D18Mit9)/K blood CD8 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD8-positive T cell quantity both 90 days 14 0.6 % 0.08 0.3 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84630 324
LEW/Rj blood CD45RC(high) CD8 T cell count to total CD8 T cell count ratio control condition Xystrakis E, et al., J Immunol 2004 Sep 1;173(5):3140-7. CD8-positive T cell quantity male 0 days 0 80.0 % 3.0 fluorescence-activated cell sorting method 0.0 0 CD45RC high CD8 to total ratio 70571 1479
BBDR/Rhw blood CD8 cell count to R73 cell count ratio specific pathogen-free condition Fuller JM, et al., Physiol Genomics. 2009 Apr 7. T cell quantity not specified 25 days-30 days 75 median 22.0 % fluorescence-activated cell sorting method 0.0 0 67844 690
BBDR/Rhw blood CD4 cell count to CD8 cell count ratio specific pathogen-free condition Fuller JM, et al., Physiol Genomics. 2009 Apr 7. T cell quantity not specified 25 days-30 days 75 median 340.0 % fluorescence-activated cell sorting method 0.0 0 67846 690
LEXF1B/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 100.0 % fluorescence-activated cell sorting method 0.0 0 69995 1280
F344/DuCrlCrlj percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 29 96.6 % fluorescence-activated cell sorting method 0.0 0 70014 1280
LEXF1B/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 110.5 d 3.47 17.7 fluorescence-activated cell sorting method 0.0 0 70018 1280
LEXF2B/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 126.0 d 5.34 23.9 fluorescence-activated cell sorting method 0.0 0 70021 1280
LEXF3/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 130.6 d 1.57 8.0 fluorescence-activated cell sorting method 0.0 0 70023 1280
LEXF5/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 19 168.0 d 12.78 55.7 fluorescence-activated cell sorting method 0.0 0 70025 1280
LEXF6A/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 139.0 d 5.73 29.2 fluorescence-activated cell sorting method 0.0 0 70026 1280
LEXF10C/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 141.5 d 7.14 32.7 fluorescence-activated cell sorting method 0.0 0 70035 1280
LEW/Rj blood CD45RC(high) CD8 T cell count to CD45RC(low) CD8 T cell count ratio control condition Xystrakis E, et al., J Immunol 2004 Sep 1;173(5):3140-7. CD8-positive T cell quantity male 0 days 0 4.0 null 0.7 fluorescence-activated cell sorting method 0.0 0 70572 1479
BB.SHR-(D6Rat184-D6Rat3)/K blood CD45RC(low) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 30 64.6 % 1.61 8.8 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84685 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD4 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 30 37.8 % 2.15 11.8 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84625 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD8 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD8-positive T cell quantity both 90 days 10 0.8 % 0.09 0.3 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84629 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD45RC(high) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 30 4.6 % 0.53 2.9 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84682 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD45RC(high) CD4 T cell count to CD45RC(low) CD4 T cell count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 30 0.08 % 0.01 0.05 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84688 324
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 0.69 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111101 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 1.23 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111103 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 16 1.81 x 1000 cells/ul 0.08 0.32 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111108 3196
BB.SHR-(D6Rat184-D6Rat3)/K white blood cell count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. leukocyte quantity both 90 days 30 3.77 x 1000 cells/ul 214.34 1174.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75604 324
LEXF7A/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 25 88.0 % fluorescence-activated cell sorting method 0.0 0 70004 1280
LEXF7C/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 16 93.8 % fluorescence-activated cell sorting method 0.0 0 70006 1280
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 21 1215.0 cells/ul 87.07 399.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111094 3196
BBDR.BBDP-(D4Rhw11-D4Rhw10)/Rhw blood R73 cell to total mononuclear cell ratio specific pathogen-free condition Fuller JM, et al., Physiol Genomics. 2009 Apr 7. T cell quantity not specified 25 days-30 days 80 median 13.0 % fluorescence-activated cell sorting method 0.0 0 67841 690
BN/Rj blood CD45RC(high) CD8 T cell count to CD45RC(low) CD8 T cell count ratio control condition Xystrakis E, et al., J Immunol 2004 Sep 1;173(5):3140-7. CD8-positive T cell quantity male 0 days 0 0.9 null 0.1 fluorescence-activated cell sorting method 0.0 0 70573 1479
LEXF2B/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 90.0 % fluorescence-activated cell sorting method 0.0 0 69998 1280
LEXF6A/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 69.2 % fluorescence-activated cell sorting method 0.0 0 70003 1280
LEXF7B/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 55.0 % fluorescence-activated cell sorting method 0.0 0 70005 1280
LEXF8A/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 17 11.8 % fluorescence-activated cell sorting method 0.0 0 70007 1280
LEXF2A/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 107.5 d 1.75 8.0 fluorescence-activated cell sorting method 0.0 0 70020 1280
LEXF7B/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 20 125.3 d 3.8 17.0 fluorescence-activated cell sorting method 0.0 0 70028 1280
LEXF7C/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 16 136.5 d 5.98 23.9 fluorescence-activated cell sorting method 0.0 0 70029 1280
LE/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 26 158.0 d 1.82 9.3 fluorescence-activated cell sorting method 0.0 0 70038 1280
LEXF8B/Stm post-insult time to onset of T-cell lymphoma controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 25 114.0 d fluorescence-activated cell sorting method 0.0 0 70616 1280
BB.SHR-(D6Rat184-D6Rat3)/K white blood cell count control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. leukocyte quantity both 90 days 10 2.98 x 1000 cells/ul 0.28 0.87 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75605 324
BB.SHR-(D6Rat184-D6Rat3)/K blood natural killer cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. natural killer cell quantity both 90 days 10 14.7 % 0.7 2.2 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84632 324
BB.SHR-(Gnal-D18Mit9)/K blood CD25 lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. lymphocyte quantity both 90 days 14 70.5 % 1.36 5.1 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84639 324
BB.SHR-(Gnal-D18Mit9)/K blood RT6.1 positive cell count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. T cell quantity both 90 days 14 3.4 % 0.67 2.5 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84636 324
BB.SHR-(D6Rat184-D6Rat3)/K blood B lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. B cell quantity both 90 days 30 37.7 % 2.03 11.1 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75598 324
BB.SHR-(D6Rat184-D6Rat3)/K blood B lymphocyte count to total leukocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. B cell quantity both 90 days 10 31.0 % 1.9 6.0 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 75599 324
BB.SHR-(D6Rat184-D6Rat3)/K blood CD45RC(high) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 10 3.2 % 0.38 1.2 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84683 324
BB.SHR-(Gnal-D18Mit9)/K blood CD45RC(low) CD4 T lymphocyte count to total lymphocyte count ratio control condition Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. CD4-positive T cell quantity both 90 days 14 65.9 % 1.76 6.6 fluorescence-activated cell sorting method opthalmic venous plexus 0.0 0 84687 324
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 2267.0 cells/ul 74.25 315.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111093 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 0.43 x 10E6 cells/ml 0.02 0.11 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111100 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 1.1 x 10E6 cells/ml 0.02 0.09 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111102 3196
BDIX/OrlCrl blood CD4 cell count 0.9% sodium chloride solution (2 ml) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 63 days-77 days 16 2.06 x 1000 cells/ul 0.17 0.67 fluorescence-activated cell sorting method 0.0 0 days baseline baseline saline control group 111106 3196
LEXF4/Stm percentage of study population developing T-cell lymphomas during a period of time controlled N-propyl-N-nitrosourea content drinking water (400 mg/l) (for 50 days) Lu LM, et al., Br J Cancer 1999 May;80(5-6):855-61. leukocyte integrity trait not specified 40 days-365 days 21 57.1 % fluorescence-activated cell sorting method 0.0 0 70001 1280